Welcome to this podcast (18:23) brought to you by Medicom Medical Publishers about the cutting-edge science in heart failure management presented at the Heart Failure Association (HFA) 2024, a scientific congress of the European Society of Cardiology (ESC). The meeting took place 11-14 May at the Lisbon Congress Centre in Portugal and online.
Heart Failure is a life-threatening syndrome affecting more than 64 million people worldwide. Up to one-third of patients die within 1 year of hospital admission and 50-75% die within 5 years of admission. With such an important topic, what updates did we see at HFA 2024? In addition to several selected summaries of talks, we have an exclusive Meet-the-Trialist interview with Dr Jasper Brugts (Erasmus University Medical Center, Rotterdam, the Netherlands), about the late-breaking MONITOR-HF trial.
In this podcast, we cover:
- SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM
- The phase 2 MIRACLE trial in HF + CKD
- The T2D subanalysis for EMPACT-MI trial; for an exclusive interview with the Prof Javed Butler, listen here.
- SGLT2 inhibitors decrease atrial fibrillation risk in HFrEF patients
- Interview with Dr Brugts on MONITOR-HF.
Posted on
Table of Contents: HFA 2024
Featured articles
Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF
Trials: Pharmacology
Effects of semaglutide on MACE irrespective of HF status
SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM
ARIES-HM3 trial: Subgroup analysis in patients with prior need for aspirin
Three diuretic regimens compared in the DEA-HF study
Adding a mineralocorticoid receptor modulator in heart failure with CKD
SGLT2 Inhibitors
Empagliflozin did not reduce mortality for HF after MI regardless of T2D status
SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk
Trials: Other
Individualised diuretic titration in acute HF without a physician
Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF
CD34+ stem cells promote reverse cardiac remodelling after acute MI
Registries
Sex-specific outcomes and resource utilisation after HF hospitalisation
Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands
Devices
PAP-guided management system appears safe in patients with HF
Delivery of CRT guided by non-invasive anatomy assessment
RELIEVE-ing HFrEF with interatrial shunting
Miscellaneous
Algorithm-based remote patient monitoring was associated with lower mortality in a retrospective cohort study
High mortality and morbidity in suspected de novo HF in outpatient care
Bio-ADM as a marker for congestion in patients hospitalised for acute HF
Hypertonic saline not effective in ambulatory patients with heart failure?
No effect of low-dose carperitide on mortality or hospitalisation in acute HF
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com